BackUroGen Pharma Overview

UroGen Pharma Current Cash

UroGen Pharma's current cash is $79M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$79.13M
↓ 14.82% YoYΔ $-13.77M vs prior year quarter

Peer average

Loading

UroGen Pharma Current Cash History

Loading

UroGen Pharma vs. peers: Current Cash Comparison

Loading

UroGen Pharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

UroGen Pharma (URGN) FAQ

UroGen Pharma (URGN) currently reports a current cash of $79M as of June 2026. That compares with $93M in the prior-year period — down 14.8% year over year. Use the charts on this page to explore UroGen Pharma's current cash history and peer comparisons.

UroGen Pharma's current cash decreased from $93M to $79M — a 14.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

UroGen Pharma reported $79M in current cash as of June 2026. That compares with $93M in the prior-year period — down 14.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $79M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for UroGen Pharma, and consider following URGN for alerts when major investors trade the stock.

UroGen Pharma is classified in the Healthcare sector. On current cash, it currently shows $79M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing URGN with unrelated industries.